It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts,
are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non …

Hepatocellular carcinoma is one of the leading causes of cancer related death in the world.
Biannual surveillance for the disease in patients with cirrhosis and in high risk carriers of …

Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma
(HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the …

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …

Background and aims Accumulating evidence suggests that the primary and acquired
resistance of hepatocellular carcinoma (HCC) to sorafenib is mediated by multiple …

Over the past decade, sorafenib has been the only systemic agent with proven clinical
efficacy for patients with unresectable hepatocellular carcinoma (HCC). Recently, lenvatinib …

Background Hepatocellular carcinoma (HCC) is one of the most common malignancies
globally. Despite aggressive and multimodal treatment regimens, the overall survival of HCC …

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, which
ranks as the sixth of cancer-related death. Despite the emergence of targeted therapy …

Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular
carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib …

Background Hepatocellular carcinoma (HCC) is a common primary malignant tumor which
usually progresses to an advanced stage because of late diagnosis. Sorafenib (Sora) is a …